Rituximab versus Splenectomy in Chronic Primary ITP: Experience of a Single Hematology Clinic
Conclusion: The overall response revealed that splenectomy appeared superior to rituximab as a second-line treatment of ITP. Splenectomy was the only positive prognostic indicator of sustained response.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Rawanda Shamoon, Ahmed K. Yassin, Sara L. Alnuaimi Source Type: research
More News: Bleeding | Hematology | Infectious Diseases | Rituxan | Splenectomy | Study | Thrombocytopenia